Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deborah A Thomas

Showing results (61-70 of 109) with videos related to

Pageof 11
Sort By:
Blood|August 1, 2002
The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemiaAlessandra Ferrajoli, Michael J Keating, Taghi Manshouri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2002
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemiaFrancis J Giles, Guillermo Garcia-Manero, Jorge E Cortes, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 21, 2014
Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemiaStefan Faderl, Kumudha Balakrishnan, Deborah A Thomas, et al.
Blood|February 1, 2003
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapyJorge E Cortes, Moshe Talpaz, Francis Giles, et al.
Cancer|December 12, 2003
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemiaSusan M O'Brien, Hagop M Kantarjian, Deborah A Thomas, et al.
Blood|August 16, 2008
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemiaDeborah A Thomas, Susan O'Brien, Jeffrey L Jorgensen, et al.
Cancer Chemotherapy and Pharmacology|September 19, 2003
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemiaApostolia M Tsimberidou, Elihu Estey, Jorge E Cortes, et al.
AIDS (London, England)|February 9, 2002
HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patientsJudith Falloon, Mounir Ait-Khaled, Deborah A Thomas, et al.
Cancer|April 4, 2006
Thalidomide therapy for myelofibrosis with myeloid metaplasiaDeborah A Thomas, Francis J Giles, Maher Albitar, et al.
Blood|June 5, 2004
Outcome with the hyper-CVAD regimens in lymphoblastic lymphomaDeborah A Thomas, Susan O'Brien, Jorge Cortes, et al.
Pageof 11

Showing results (61-70 of 109) with videos related to

Sort By:
Pageof 11
Blood|August 1, 2002
The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemiaAlessandra Ferrajoli, Michael J Keating, Taghi Manshouri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2002
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemiaFrancis J Giles, Guillermo Garcia-Manero, Jorge E Cortes, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 21, 2014
Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemiaStefan Faderl, Kumudha Balakrishnan, Deborah A Thomas, et al.
Blood|February 1, 2003
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapyJorge E Cortes, Moshe Talpaz, Francis Giles, et al.
Cancer|December 12, 2003
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemiaSusan M O'Brien, Hagop M Kantarjian, Deborah A Thomas, et al.
Blood|August 16, 2008
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemiaDeborah A Thomas, Susan O'Brien, Jeffrey L Jorgensen, et al.
Cancer Chemotherapy and Pharmacology|September 19, 2003
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemiaApostolia M Tsimberidou, Elihu Estey, Jorge E Cortes, et al.
AIDS (London, England)|February 9, 2002
HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patientsJudith Falloon, Mounir Ait-Khaled, Deborah A Thomas, et al.
Cancer|April 4, 2006
Thalidomide therapy for myelofibrosis with myeloid metaplasiaDeborah A Thomas, Francis J Giles, Maher Albitar, et al.
Blood|June 5, 2004
Outcome with the hyper-CVAD regimens in lymphoblastic lymphomaDeborah A Thomas, Susan O'Brien, Jorge Cortes, et al.
Pageof 11